Hydroxychloroquine in the eyes of "systemic rheumatoid lupus"

Hydroxychloroquine (HCQ), a disease-modifying antirheumatic drug used in the treatment of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), together with methotrexate and sulfasalazine, forms the backbone of triple therapy for .

In SLE, HCQ is recommended as the cornerstone of treatme.

Treatment improves patient survival, reduces disease activity, reduces kidney damage, and reduces the risk of serious comorbidities, including thromboembolic disease and pregnancy complicatio.

The drug is generally safe and can be prescribed to pregnant wom.

Because the new method showed that patients who received lower doses did not experience retinal damage at all when they received higher doses or cumulatively over long periods of ti.

Routine monitoring of HCQ-treated patients using computer-controlled perimeter and OCT methods is now recommended and may help detect retinal toxicity before central vision is affect.

Based on the above, the recommendations for monitoring of patients treated with HCQ have changed :

HCQ is an agent with many beneficial effects in patients with SLE and other connective tissue disorders, and HCQ rarely causes visual impairment in subsequent treatmen.

Prescribing physicians should be aware of national and international drug use guidelines and monitor patients in accordance with these guidelines, but without being subject to undue tightness and unnecessary fe.

Expert Opinion:

 

references:

references:

Troldborg A, Bay-Laurberg T, Clemmensen K, Andersen J, Deleuran.

Troldborg A, Bay-Laurberg T, Clemmensen K, Andersen J, Deleuran.

Ponticelli C, Moroni.

leave a message here